Ben Beerle

Cooley advised Alumis (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, on its definitive agreement with ACELYRIN to merge in an all-stock transaction.

Cooley advised Candid Therapeutics, a biotechnology company dedicated to developing potentially transformative drugs to address autoimmune diseases, on its $370 million debut capital raise and three-way merger with Vignette Bio and TRC 2004.

Cooley advised Accel, a long-standing investor of Squarespace, in connection with Squarespace’s definitive agreement to go private by Permira in an approximately $6.9 billion all-cash transaction.

Cooley advised Sazerac, one of the world’s largest distilled spirits companies, on its agreement to acquire BuzzBallz, a woman-owned and family-operated distillery, winery and brewery in Texas.

Cooley advised RayzeBio, a clinical-stage radiopharmaceutical therapeutics (RPT) company with an innovation-leading position in actinium-based RPTs and a pipeline of potentially first-in-class and best-in-class drug development programs, on its definitive agreement to be acquired by Bristol Myers Squibb.